News | December 14, 2022
JB Pharma to buy Glenmark's ‘Razel’ for Rs. 314 crore in India and Nepal
The acquisition marks JB Pharma’s entry into the ‘Statin’ segment which is the largest group in the cardiac therapy
The acquisition marks JB Pharma’s entry into the ‘Statin’ segment which is the largest group in the cardiac therapy
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
J. B. Chemicals & Pharmaceuticals has informed that the acquisition of the Razel franchise from Glenmark Pharmaceuticals Limited has been successfully completed.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)